This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nuvalent (NUVL), Abbott Laboratories (ABT) and Abivax SA Sponsored ADR (ABVX)

Tipranks - Tipranks - Wed Jun 3, 5:00AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nuvalent (NUVL), Abbott Laboratories (ABT) and Abivax SA Sponsored ADR (ABVX).

Claim 55% Off TipRanks

Nuvalent (NUVL)

Wells Fargo analyst Eva Fortea Verdejo maintained a Buy rating on Nuvalent yesterday and set a price target of $116.00. The company’s shares closed last Monday at $93.01.

According to TipRanks.com, Verdejo is a 5-star analyst with an average return of 41.3% and a 75.4% success rate. Verdejo covers the Healthcare sector, focusing on stocks such as Bicara Therapeutics Inc., Zentalis Pharmaceuticals, and Kiniksa Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nuvalent with a $143.44 average price target, representing a 29.8% upside. In a report issued on May 22, Canaccord Genuity also maintained a Buy rating on the stock with a $126.00 price target.

See the top stocks recommended by analysts >>

Abbott Laboratories (ABT)

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories, with a price target of $109.00. The company’s shares closed last Monday at $87.78.

According to TipRanks.com, Biegelsen is a 2-star analyst with an average return of 0.3% and a 47.0% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Inspire Medical Systems, and Zimmer Biomet Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Laboratories with a $119.76 average price target, which is a 39.6% upside from current levels. In a report issued on May 29, Piper Sandler also maintained a Buy rating on the stock with a $115.00 price target.

Abivax SA Sponsored ADR (ABVX)

Jefferies analyst Faisal Khurshid downgraded Abivax SA Sponsored ADR to Hold yesterday and set a price target of $90.00. The company’s shares closed last Monday at $129.69.

According to TipRanks.com, Khurshid is a 5-star analyst with an average return of 68.6% and a 62.1% success rate. Khurshid covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Syndax Pharmaceuticals, and Viridian Therapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Abivax SA Sponsored ADR with a $148.13 average price target, implying an 11.3% upside from current levels. In a report issued on May 18, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $112.00 price target.

Read More on NUVL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).